Evidence map›Paper›PMID 32484608›Full record

ArticleBrain and behavior2020

Alzheimer's amyloid-β and tau protein accumulation is associated with decreased expression of the LDL receptor-associated protein in human brain tissue.

Claire E Shepherd, Andrew J Affleck, Anita Y Bahar, Francine Carew-Jones, Gillian Gregory, David H Small, Glenda M Halliday

Open access · goldAbstract read
In one paragraph

Article in Brain and behavior, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Claire E ShepherdNeuroscience Research Australia, Randwick, Sydney, NSW, Australia.ORCID 0000-0002-0399-3218
Andrew J AffleckNeuroscience Research Australia, Randwick, Sydney, NSW, Australia.ORCID 0000-0003-4686-9003
Anita Y BaharNeuroscience Research Australia, Randwick, Sydney, NSW, Australia.
Francine Carew-JonesNeuroscience Research Australia, Randwick, Sydney, NSW, Australia.ORCID 0000-0001-5323-0879
Gillian GregoryNeuroscience Research Australia, Randwick, Sydney, NSW, Australia.
David H SmallMenzies Research Institute, University of Tasmania, Hobart, TAS, Australia.
Glenda M HallidayNeuroscience Research Australia, Randwick, Sydney, NSW, Australia.ORCID 0000-0003-0422-8398
UNSW Sydney · AUNeuroscience Research Australia · AUThe University of Sydney · AUUniversity of Tasmania · AU

Funding

National Health and Medical Research Council of Australia 1079679National Health and Medical Research Council of Australia 1095127National Health and Medical Research Council of Australia 605530Rebecca Cooper Foundation
6 · The paper itself

Abstract

introductionOne of the major neuropathological features of Alzheimer's disease (AD) is the accumulation of amyloid-β (Aβ) protein in the brain. Evidence suggests that the low-density lipoprotein receptor-associated protein (RAP) binds strongly to Aβ and enhances its cellular uptake and that decreased RAP expression correlates with increased Aβ production in animal models of AD.

methodsThe current study examined whether RAP levels change in AD human brain tissue and whether they are related to the amount of AD pathology. RAP and NeuN levels were determined by Western blot, while low-density lipoprotein receptor-related protein 1 (LRP1), tau and Aβ levels were determined by ELISA in the temporal cortex of 17 AD and 16 control cases.

resultsAn increase in total Aβ and insoluble and soluble tau protein was observed in AD brain tissue. In contrast, RAP levels were significantly decreased in AD brain tissue compared to controls. Correlation analysis revealed that levels of RAP correlated with both total Aβ and soluble and insoluble tau levels. Neither LRP1 nor NeuN levels were significantly altered in AD brain tissue homogenates and did not correlate with Aβ or tau protein levels.

conclusionReduction in RAP may contribute to the accumulation and aggregation of Aβ in the AD brain.

Indexed as

Alzheimer Diseasetau ProteinsAmyloid beta-PeptidesAnimalsBrainHumansLDL-Receptor Related Protein-Associated ProteinAmyloid beta-PeptidesLDL-Receptor Related Protein-Associated Proteintau ProteinsAlzheimer's diseaseamyloid-βELISAreceptor-associated proteintau

Identifiers

PMID32484608
PMCPMC7375106
OpenAlexW3030980062

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.